AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37910805 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Patient-Reported Outcome Instrument
Number of subjects: 0
Study 37910822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Chemotherapy
Number of subjects: 0
Study 37910822 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Chemotherapy
Number of subjects: 0
Study 37913505 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg thalidomide
Number of subjects: 150
Study 37913505 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg thalidomide
Number of subjects: 150
Study 37913505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 37913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of steps
Number of subjects: 31
Study 37913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sleep proportion
Number of subjects: 31
Study 37913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Median heart rate
Number of subjects: 31
Study 37913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion very active
Number of subjects: 31
Study 37913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of floors
Number of subjects: 31
Study 37913818 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica + Standard Therapy (ST)
Number of subjects: 60
Study 37913818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide Polysulfate (MPSP) + Standard Therapy (ST)
Number of subjects: 60
Study 37913818 — intervention group
Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 60
Study 37913853 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch and iPhone used for routine ECG recording
Number of subjects: 1420
Study 37913936 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulators as solo therapy
Number of subjects: 129
Study 37913936 — intervention group
Group type: COMPARATOR
Intervention: Prokinetics as solo new therapy
Number of subjects: 129
Study 37913936 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetics combined with gastroparesis diets or neuromodulators
Number of subjects: 129
Study 37913936 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulators as solo new therapy with nondelayed gastric emptying
Number of subjects: 129
Study 37914086 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan (LNP023)
Number of subjects: 0
Study 37914086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37914178 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy sleep duration (HSD; 9.5 hours in bed/night)
Number of subjects: 31
Study 37914178 — intervention group
Group type: COMPARATOR
Intervention: Restricted sleep (RS; 6.5 hours in bed/night)
Number of subjects: 31
Study 37914392 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB 17 device
Number of subjects: 163
Study 37914482 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m²)
Number of subjects: 606
Study 37914482 — intervention group
Group type: COMPARATOR
Intervention: 3+7 chemotherapy
Number of subjects: 606
Study 37914482 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 606
Study 37914483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cusatuzumab 10 mg/kg
Number of subjects: 103
Study 37914483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cusatuzumab 20 mg/kg
Number of subjects: 103
Study 37914581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 0
Study 37914581 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 0
Study 37914581 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural sleep
Number of subjects: 0
Study 37914581 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 0
Study 37914594 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily for 5 years
Number of subjects: 0
Study 37914804 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL (low-density lipoproteins)
Number of subjects: 40
Study 37914804 — intervention group
Group type: EXPERIMENTAL
Intervention: High-apoB subjects
Number of subjects: 40
Study 37914804 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-induced WAT IL-1β-secretion
Number of subjects: 40
Study 37914804 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for IL-1β-secretion
Number of subjects: 40
Study 37914855 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with ASDs
Number of subjects: 438
Study 37914855 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 438
Study 37914976 — intervention group
Group type: EXPERIMENTAL
Intervention: NYM016 (novel small-molecule PSMA-targeted fluorescence probe)
Number of subjects: 0
Study 37914983 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab)
Number of subjects: 903
Study 37914983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study 37915038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal idursulfase-IT
Number of subjects: 47
Study 37915038 — intervention group
Group type: COMPARATOR
Intervention: No intrathecal idursulfase-IT
Number of subjects: 47
Study 37915038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal idursulfase-IT (children aged < 6 years)
Number of subjects: 47
Study 37915038 — intervention group
Group type: COMPARATOR
Intervention: No intrathecal idursulfase-IT (children aged < 6 years)
Number of subjects: 47
Study 37915337 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced vitamin C serum (eVCS)
Number of subjects: 29
Study 37915337 — intervention group
Group type: EXPERIMENTAL
Intervention: eVCS and retinol-bakuchiol serum (RBS) combination
Number of subjects: 29
Study 37915337 — intervention group
Group type: EXPERIMENTAL
Intervention: eVCS-RSB combination
Number of subjects: 29
Study 37915337 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 37915438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based music therapy (MBMT)
Number of subjects: 92
Study 37915438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (MI)
Number of subjects: 92
Study 37915546 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 mg bid + Selenium 100 mcg
Number of subjects: 120
Study 37915546 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 350 mg bid + TA-65 (Astragalus Membranaceus extract) 100U
Number of subjects: 120
Study 37915546 — intervention group
Group type: COMPARATOR
Intervention: Placebo-1 bid + Placebo-2
Number of subjects: 120
Study 37915546 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary variables (handgrip strength, aerobic capacity at the step test and quality of life)
Number of subjects: 120
Study 37915619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing zinc, vitamins B, calcium, iodine, iron, β-carotene, and folic acid
Number of subjects: 0
Study 37915619 — intervention group
Group type: COMPARATOR
Intervention: Control supplement containing calcium, iodine, iron, β-carotene, and folic acid
Number of subjects: 0
Study 37915911 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week supervised exercise intervention (two sessions per week for 4 weeks, totaling eight sessions)
Number of subjects: 34
Study 37915911 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week supervised exercise intervention
Number of subjects: 34
Study 37915938 — intervention group
Group type: EXPERIMENTAL
Intervention: HDx (expanded hemodialysis)
Number of subjects: 0
Study 37915938 — intervention group
Group type: COMPARATOR
Intervention: OL-HDF (online hemodiafiltration)
Number of subjects: 0
Study 37916028 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) once-weekly semaglutide
Number of subjects: 0
Study 37916028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37916266 — intervention group
Group type: EXPERIMENTAL
Intervention: MMBV test
Number of subjects: 736
Study 37916266 — intervention group
Group type: COMPARATOR
Intervention: Physician's etiological suspicion
Number of subjects: 736
Study 37916303 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg administered twice daily for 8 weeks
Number of subjects: 27
Study 37916412 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 68
Study 37916412 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 68
Study 37916412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 37916517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with SBP target <120 mmHg, TTR calculated based on SBP measurements during the first 3-month follow-up.
Number of subjects: 7965
Study 37916517 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with SBP target <140 mmHg, TTR calculated based on SBP measurements during the first 3-month follow-up.
Number of subjects: 7965
Study 37916620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibeprenlimab 2 mg/kg
Number of subjects: 155
Study 37916620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibeprenlimab 4 mg/kg
Number of subjects: 155
Study 37916620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibeprenlimab 8 mg/kg
Number of subjects: 155
Study 37916620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 37916745 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant therapy
Number of subjects: 10468
Study 37916843 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (WW, WeightWatchers)
Number of subjects: 61
Study 37916843 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 61
Study 37916926 — intervention group
Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 1089
Study 37916926 — intervention group
Group type: COMPARATOR
Intervention: laTME
Number of subjects: 1089
Study 37916926 — intervention group
Group type: EXPERIMENTAL
Intervention: taTME and laTME
Number of subjects: 1089
Study 37917058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal.
Number of subjects: 327
Study 37917058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab treatment.
Number of subjects: 327
Study 37917063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Blood Pressure Reduction (MB-BP) program
Number of subjects: 201
Study 37917063 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 201
Study 37917111 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Tears
Number of subjects: 0
Study 37917111 — intervention group
Group type: COMPARATOR
Intervention: Control (no artificial tears)
Number of subjects: 0
Study 37917140 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly outpatient rehabilitation intervention (weekly physical and occupational therapy for 11 weeks)
Number of subjects: 0
Study 37917140 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly outpatient rehabilitation intervention
Number of subjects: 0
Study 37917146 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Well Check (n=61)
Number of subjects: 123
Study 37917146 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (n=62)
Number of subjects: 123
Study 37917187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg daily in 28-day cycles
Number of subjects: 29
Study 37917211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Intrapulmonary Deflation (IID)
Number of subjects: 1
Study 37917211 — intervention group
Group type: COMPARATOR
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 1
Study 37917218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone targeted agents (BTAs)
Number of subjects: 881
Study 37917218 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 881
Study 37917218 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 881
Study 37917289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Number of subjects: 12
Study 37917417 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight obesity (NWO)
Number of subjects: 40
Study 37917417 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity (MHO)
Number of subjects: 40
Study 37917417 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CON)
Number of subjects: 40
Study 37917417 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy obesity (MUO)
Number of subjects: 40
Study 37917438 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom catastrophizing
Number of subjects: 0
Study 37917638 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic undernutrition
Number of subjects: 918
Study 37917638 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental lag
Number of subjects: 918
Study 37917638 — intervention group
Group type: EXPERIMENTAL
Intervention: At risk of neurodevelopmental delay
Number of subjects: 918
Study 37917638 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of stunting and suboptimal neurodevelopment
Number of subjects: 918
Study 37917638 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of child development
Number of subjects: 918
Study 37917826 — intervention group
Group type: EXPERIMENTAL
Intervention: levcromakalim (50 µg/mL)
Number of subjects: 21
Study 37917826 — intervention group
Group type: COMPARATOR
Intervention: placebo (isotonic saline)
Number of subjects: 21
Study 37917913 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37917943 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous calcium chloride
Number of subjects: 120
Study 37917943 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 120
Study 37918066 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention consisting of five activities
Number of subjects: 106
Study 37918066 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study 37918129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cx611
Number of subjects: 83
Study 37918129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 37918404 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO (125-1,000 mg/m)
Number of subjects: 41
Study 37918404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 37918417 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based approach (symptom-based tuberculosis screening by community health workers, TPT initiation by nurse in household, home visits for follow-up)
Number of subjects: 2894
Study 37918417 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based approach
Number of subjects: 2894
Study 37918417 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care facility-based approach (control group)
Number of subjects: 2894
Study 37918674 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (2 μg daily)
Number of subjects: 600
Study 37918675 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon-containing Mediterranean-style diet
Number of subjects: 41
Study 37918675 — intervention group
Group type: COMPARATOR
Intervention: Control group (other 99 MED foods)
Number of subjects: 41
Study 37918685 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe (ENDO-AID)
Number of subjects: 766
Study 37918790 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia (target BIS values of 40-60)
Number of subjects: 163
Study 37918790 — intervention group
Group type: COMPARATOR
Intervention: Control group (sevoflurane dose determined by anaesthesiologist)
Number of subjects: 163
Study 37918790 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 163
Study 37918855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovleplenib (oral Syk inhibitor)
Number of subjects: 0
Study 37918921 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Fracture Centers (GFCs)
Number of subjects: 0
Study 37918921 — intervention group
Group type: COMPARATOR
Intervention: Usual care centres
Number of subjects: 0
Study 37918933 — intervention group
Group type: EXPERIMENTAL
Intervention: PERSARC (personalised risk assessment tool)
Number of subjects: 120
Study 37918933 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 120
Study 37918956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy followed by inguinofemoral lymph node dissection in group 1 (tumors ≥4 cm)
Number of subjects: 64
Study 37918956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy followed by inguinofemoral lymph node dissection in group 2 (multifocal tumors)
Number of subjects: 64
Study 37918956 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-positive patients (32% had micrometastasis or isolated tumor cells only)
Number of subjects: 64
Study 37919179 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy®
Number of subjects: 96
Study 37919179 — intervention group
Group type: EXPERIMENTAL
Intervention: DistrACTION® Cards
Number of subjects: 96
Study 37919179 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 37919269 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy with oleclumab (arm A)
Number of subjects: 127
Study 37919269 — intervention group
Group type: COMPARATOR
Intervention: Chemo-immunotherapy without oleclumab (arm B)
Number of subjects: 127
Study 37919313 — intervention group
Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 20
Study 37919438 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous bone marrow aspirate concentrate (n=120)
Number of subjects: 480
Study 37919438 — intervention group
Group type: EXPERIMENTAL
Intervention: umbilical cord tissue-derived mesenchymal stromal cells (n=120)
Number of subjects: 480
Study 37919438 — intervention group
Group type: EXPERIMENTAL
Intervention: stromal vascular fraction (n=120)
Number of subjects: 480
Study 37919438 — intervention group
Group type: COMPARATOR
Intervention: corticosteroid injection (CSI) (n=40)
Number of subjects: 480
Study 37919448 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF chemotherapy followed by surgery
Number of subjects: 47
Study 37919456 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV DNA load < 4.05 log10 copies/ml at ICANS onset
Number of subjects: 79
Study 37919456 — intervention group
Group type: EXPERIMENTAL
Intervention: Falling or stable TTV DNA load between lymphodepletion and CAR-T infusion
Number of subjects: 79
Study 37919483 — intervention group
Group type: COMPARATOR
Intervention: ASC42 5-200 mg (SAD)
Number of subjects: 65
Study 37919483 — intervention group
Group type: COMPARATOR
Intervention: ASC42 5-50 mg (MAD) once-daily for 14 days
Number of subjects: 65
Study 37919483 — intervention group
Group type: COMPARATOR
Intervention: ASC42 15 mg with a high-fat meal
Number of subjects: 65
Study 37919483 — intervention group
Group type: COMPARATOR
Intervention: ASC42 (various doses)
Number of subjects: 65
Study 37919483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 37919512 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 67
Study 37919512 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 67
Study 37919617 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide choline extended-release tablet (DCCR)
Number of subjects: 125
Study 37919629 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative portal flow pulsatility
Number of subjects: 389
Study 37919629 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative splenic pulsatility indices
Number of subjects: 389
Study 37919629 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal pulsatility index
Number of subjects: 389
Study 37919630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova StatStrip glucometer
Number of subjects: 135
Study 37919630 — intervention group
Group type: COMPARATOR
Intervention: High-dose insulin therapy (HNC)
Number of subjects: 135
Study 37919668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg or 840 mg once daily with standard doses of everolimus for RCC
Number of subjects: 135
Study 37919668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg or 840 mg once daily with standard doses of docetaxel for GC
Number of subjects: 135
Study 37919668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg or 840 mg once daily with standard doses of cetuximab for CRC
Number of subjects: 135
Study 37919668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg or 840 mg once daily
Number of subjects: 135
Study 37919676 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-led huddles
Number of subjects: 42
Study 37919695 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheal extubation
Number of subjects: 213
Study 37919695 — intervention group
Group type: COMPARATOR
Intervention: Prolonged mechanical ventilation
Number of subjects: 213
Study 37919695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 213
Study 37919695 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell infusion
Number of subjects: 213
Study 37919695 — intervention group
Group type: EXPERIMENTAL
Intervention: Postreperfusion syndrome
Number of subjects: 213
Study 37919695 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperations
Number of subjects: 213
Study 37919695 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU readmissions
Number of subjects: 213
Study 37919697 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly Nuvaring® (vaginal ring)
Number of subjects: 33
Study 37919697 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily combined oral contraceptive (daily pills)
Number of subjects: 33
Study 37919697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-monthly injectable contraceptive (injectable)
Number of subjects: 33
Study 37919697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 33
Study 37919697 — intervention group
Group type: COMPARATOR
Intervention: Daily pills
Number of subjects: 33
Study 37919697 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable
Number of subjects: 33